Myelosuppression by sunitinib is flt-3 genotype dependent

@inproceedings{Erp2010MyelosuppressionBS,
  title={Myelosuppression by sunitinib is flt-3 genotype dependent},
  author={Nicole van Erp and Ron H. J. Mathijssen and Astrid A. M. van der Veldt and John B A G Haanen and An K L Reyners and K Eechoute and Epie Boven and J A M Wessels and H-J Guchelaar and Hans A.J. Gelderblom},
  booktitle={British Journal of Cancer},
  year={2010}
}
NP van Erp*, RHJ Mathijssen, AA van der Veldt, JB Haanen, AKL Reyners, K Eechoute, E Boven, JAM Wessels, H-J Guchelaar and H Gelderblom Departments of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands; Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-6 of 6 references

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

  • GD Demetri, AT van Oosterom, +14 authors PG Casali
  • Lancet 368:
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…